Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

NCT03032614 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Lack of funding

Conditions

Breast Cancer Stage IV
Ovarian Cancer
BRCA1 Mutation
BRCA2 Mutation

Interventions

DRUG: Carboplatin
DRUG: Eribulin
DRUG: Veliparib

Sponsor

The University of Texas Health Science Center at San Antonio